Cargando…
IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases
Since SARS-CoV-2 appeared in late 2019, many studies on the immune response to COVID-19 have been conducted, but the asymptomatic or light symptom cases were somewhat understudied as respective individuals often did not seek medical help. Here, we analyze the production of the IgG antibodies to vira...
Autores principales: | Tutukina, Maria, Kaznadzey, Anna, Kireeva, Maria, Mazo, Ilya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539461/ https://www.ncbi.nlm.nih.gov/pubmed/34696374 http://dx.doi.org/10.3390/v13101945 |
Ejemplares similares
-
BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19
por: Kaznadzey, Anna, et al.
Publicado: (2022) -
Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022) -
Dual-Antigen System Allows Elimination of False Positive Results in COVID-19 Serological Testing
por: Komarov, Andrei, et al.
Publicado: (2021) -
IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays
por: Shah, Jyotsna, et al.
Publicado: (2021) -
IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection
por: Choudhary, Hari Ram, et al.
Publicado: (2021)